Navigation Links
Pearl Therapeutics, Inc. Expands Its Senior Management Team With Top Talent in Clinical Development and Regulatory Affairs
Date:12/20/2007

REDWOOD CITY, Calif., Dec. 20 /PRNewswire/ -- Pearl Therapeutics, Inc., a biopharmaceutical company developing treatments for major respiratory diseases, today announced the appointment of Colin Reisner, MD, FCCP, FAAAAI to the position of Chief Medical Officer and Executive Vice President of Clinical Development and Medical Affairs, and Michael Golden to the position of Vice President, Regulatory Affairs and Quality.

"We are delighted to welcome Colin and Michael as we continue to build our team with experts in the development of respiratory products," said Adrian Smith, President, Pearl Therapeutics, Inc. "Both Colin and Michael have proven records of success in the pharmaceutical industry and are innovative leaders who have designed and managed the clinical and CMC development programs of many marketed products, from pre-clinical through NDA filing and commercialization."

Dr. Reisner joins Pearl from Novartis Pharmaceuticals where he was Executive Director and former Disease Area Section Head for Global Respiratory Development, a position focused on both clinical development leadership and shaping Novartis' global strategy for respiratory products. He led the clinical development activities of several programs in asthma, COPD, and cystic fibrosis, assessing single and combination therapies across a wide range of delivery systems and dosage forms. Earlier at Novartis, Dr. Reisner served as the Global Brand Medical Director for Xolair(R), the first biologic agent approved for asthma. In this capacity, he oversaw all clinical activities ranging from design and implementation of the pediatric development program to the European approval for the treatment of severe persistent allergic asthma.

Prior to Novartis, Dr. Reisner served as Senior Director in the Respiratory Division at GlaxoSmithKline, and as the International Project Leader for beta agonists. Dr. Reisner played a diverse and integral role in the development of several key product
'/>"/>

SOURCE Pearl Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pearl Therapeutics Raises $15.5 Million in Private Financing
2. String of fullerene pearls
3. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
4. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
5. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
6. Nile Therapeutics, Inc. Adds to Executive Management Team
7. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
8. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
9. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
10. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
11. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Indianapolis, IN (PRWEB) December 17, 2014 ... for Laboratory Excellence following its most recent COLA ... Accreditation by COLA, a national healthcare accreditation organization. ... rigid standards of quality in day-to-day operations, demonstrate ... and pass a rigorous on-site laboratory survey. ...
(Date:12/17/2014)...  Vermillion, Inc. (NASDAQ: VRML ), a ... the next step in its expanded strategy to rebuild ... the naming of current Chief Operating Officer, Valerie ... current Chairman of the Board and CEO James ... changes are effective January 1, 2015. "Jim ...
(Date:12/17/2014)... Calif. , Dec. 17, 2014 ... a Phase 2 study evaluating the investigational oral ... of patients with severe, chronic itch who are ... of care, including topical steroids and antihistamines. ... change in Visual Analog Scale (VAS) itch score ...
(Date:12/15/2014)... & PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult ... wholly-owned subsidiary Brainstorm Cell Therapeutics Ltd. was awarded a ... Office of the Chief Scientist (OCS).  This ... receipt of grant support from the Office of the ...
Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3
... , , , ... , , SAN DIEGO, CA, August ... a company focused on using proprietary taste receptor-based technologies to discover novel ... a corporate update and reported financial results for the second quarter ended ...
... , , , ... Inc., a biotechnology company developing antiviral therapies, announced today that ... C Virus (HCV) technology from Stanford University. This technology, discovered ... Jeffrey Glenn, M.D., Ph.D., is focused on a variety of ...
... , , SAN DIEGO, Aug. ... scheduled to present at the Canaccord Adams 29th Annual Global Growth ... 2:00 p.m. Eastern Time. , , (Logo: ... these presentations will be accessible on the Company,s website at ...
Cached Biology Technology:SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND SECOND QUARTER 2009 FINANCIAL RESULTS 13Eiger BioPharmaceuticals Acquires Exclusive License to Novel Hepatitis C Virus (HCV) Technology From Stanford University 2Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference 2
(Date:12/11/2014)... , Dec. 10, 2014  Data Sciences International ... has released a new series of digital telemetry ... toxicology researchers. M series, part of the PhysioTel™ ... the best possible physiologic data when incorporating functional ... functional endpoints to toxicology studies has evolved from ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/3/2014)... Dec. 2, 2014   Marvin Test Solutions ... test solutions for military, aerospace, and manufacturing organizations, ... its successful TS-900 PXI semiconductor test platform ... of high-end systems to customers at a fraction ... to traditional ATE. "Our semiconductor ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 2Marvin Test Solutions Brings New Capabilities to PXI-Based Semiconductor Test with TS-960 3
... Center researchers have discovered how the brain creates a scent ... in mice, the researchers found that nerve cells in the ... the nose -- do not perceive complex scent mixtures as ... Instead, these nerve cells, or neurons, detect the host of ...
... personalized medicine, Howard Hughes Medical Institute investigator Brian J. ... identify previously unknown genetic mutations that can trigger cancerous ... ?inside acute myeloid leukemia (AML) cells, the researchers have ... on molecular abnormalities that might be vulnerable to specific ...
... oceans, their significance as the most important resource for the ... at the centre of discussion during the seminar 'A new ... 2006) in Munich. The primary focus of the seminar will ... potential benefits for industries and society. Friedhelm Schröder and Wilhelm ...
Cached Biology News:Researchers show how brain decodes complex smells 2New strategy rapidly identifies cancer targets 2New strategy rapidly identifies cancer targets 3A new look at the state of the oceans 2A new look at the state of the oceans 3
...
...
with GlutaMAXIL-glutamine...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Biology Products: